Morphea‐like changes in the setting of cancer immunotherapy

Immune checkpoint inhibitors (ICI) are monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed death ligand 1 (PD-L1). The spectrum of immunotherapy-induced adverse reactions is unique and referred as immune-related...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the European Academy of Dermatology and Venereology 2021-10, Vol.35 (10), p.e684-e685
Main Authors: De Simone, C., Mannino, M., Sollena, P., Deilhes, F., Sibaud, V., Peris, K.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors (ICI) are monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed death ligand 1 (PD-L1). The spectrum of immunotherapy-induced adverse reactions is unique and referred as immune-related adverse events (irAEs). Cutaneous toxicities account for approximately 30% of all irAEs; the most common include eczema-like maculopapular rash, pruritus, lichenoid reactions, vitiligo-like lesions, psoriasis, and, less frequently, bullous pemphigoid or sarcoidosis. Sclerotic reactions as scleroderma and morphea have been rarely described. A recent review reported 6 cases of scleroderma and 4 cases of morphea. We describe two cases of ICI-related morphea-like reactions.
ISSN:0926-9959
1468-3083
DOI:10.1111/jdv.17388